Arbutus to Report Second Quarter 2019 Financial Results
July 29 2019 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that it has scheduled its second quarter financial
results, conference call and webcast for Monday, August 5, 2019.
The schedule for the press release and conference
call/webcast are as follows:
• |
Q2 2019 Press Release: |
August 5, 2019 at 7:30 a.m. ET |
• |
Q2 2019 Conference Call: |
August 5, 2019 at 8:45 a.m. ET |
• |
Domestic Dial-In Number: |
(866) 393-1607 |
• |
International Dial-In Number: |
(914) 495-8556 |
• |
Conference ID Number: |
2098024 |
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling (855) 859-2056 or (404)
537-3406, and reference conference ID 2098024.
About ArbutusArbutus Biopharma
Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical
company dedicated to discovering, developing, and commercializing a
cure for patients suffering from chronic Hepatitis B (HBV)
infection. Arbutus is developing multiple drug candidates, each of
which have the potential to improve upon the standard of care and
contribute to a curative combination regimen. For more information,
visit www.arbutusbio.com.
Contact Information
InvestorsWilliam H. Collier President and CEO
Phone: 604-419-3200 Email: ir@arbutusbio.com
MediaPam Murphy Investor Relations Consultant
Phone: 604-419-3200 Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024